home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
HaCKeRz KrOnIcKLeZ 3
/
HaCKeRz_KrOnIcKLeZ.iso
/
drugs
/
60.fr.24649
< prev
next >
Wrap
Text File
|
1996-05-06
|
13KB
|
228 lines
<ARTICLE>
Date="05/09/95"
Citation="60 FR 24649"
Group="legal"
Type="NOTICE"
Department="DEPARTMENT OF JUSTICE"
Agency="DRUG ENFORCEMENT ADMINISTRATION"
Subject="Controlled Substances: Proposed 1995 Aggregate Production Quotas"
<HEADER>
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[DEA No. 132P]
Controlled Substances: Proposed 1995 Aggregate Production Quotas
AGENCY: Drug Enforcement Administration.
ACTION: Notice of proposed revised aggregate production quotas
for 1995.
</HEADER>
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[DEA No. 132P]
Controlled Substances: Proposed 1995 Aggregate Production Quotas
AGENCY: Drug Enforcement Administration.
ACTION: Notice of proposed revised aggregate production quotas
for 1995.
+
------------------------------------------------------------
SUMMARY: This notice proposes revised 1995 aggregate production
quotas for controlled substances in Schedules I and II, as required
under the Controlled Substances Act of 1970.
DATES: Comments or objections should be received on or before
June 8, 1995.
ADDRESSES: Send comments or objections to the Administrator,
Drug Enforcement Administration, Washington, DC 20537, Attn:
DEA Federal Register Representative/CCR.
FOR FURTHER INFORMATION CONTACT: Howard McClain, Jr., Chief,
Drug & Chemical Evaluation Section, Drug Enforcement Administration,
Washington, DC 20537, Telephone: (202) 307-7183.
SUPPLEMENTARY INFORMATION: Section 306 of the Controlled Substances
Act (CSA) (21 U.S.C. 826) requires that the Attorney General
establish aggregate production quotas for all controlled substances
listed in Schedules I and II. This responsibility has been delegated
to the Administrator of the DEA pursuant to sec 0.100 of Title
28 of the Code of Federal Regulations.
The Administrator, in turn, has redelegated this function
to the Deputy Administrator of the DEA by sec 0.104 of Title 28
of the Code of Federal Regulations.
On October 20, 1994, a notice of the 1995 established aggregate
production quotas was published in the Federal Register (59
FR 52991). The notice stipulated that the Deputy Administrator
of the DEA would adjust the quotas in early 1995 as provided
for in Title 21, Code of Federal Regulations, sec 1303.23(c).
These aggregate production quotas represent those amounts of
controlled substances that may be produced in the United States
in 1995 and do not include amounts which may be imported for
use in industrial processes.
The proposed revisions are based on a review of 1994 year-
end inventories, 1994 disposition data submitted by quota applicants,
estimates of the medical needs of the United States submitted
to the DEA by the Food and Drug Administration and other information
available to the DEA.
Therefore, under the authority vested in the Attorney General
by section 306 of the CSA of 1970 (21 U.S.C. 826), delegated
to the Administrator by sec 0.100 of Title 28 of the Code of Federal
Regulations, and redelegated to the Deputy Administrator by
sec 0.104 of Title 28 of the Code of Federal Regulations, the
Deputy Administrator of the DEA hereby proposes the following
changes in the 1995 aggregate production quotas for the listed
controlled substances, expressed in grams of anhydrous acid
or base.
----------------------------------------------------+---------------+-----------------
| Previously | Proposed
| established | revised 1995
Basic class | 1995 | aggregate
| aggregate | production
| production | quotas
| quotas |
----------------------------------------------------+---------------+-----------------
| |
Schedule I: | |
Acetylmethadol .................................. | 2 | 7
Alphacetymethadol ............................... | 0 | 5
Aminorex ........................................ | 2 | 7
Bufotenine ...................................... | 10 | 10
Cathinone ....................................... | 4 | 9
Difenoxin ....................................... | 14,000 | 14,00
---- page 24650 ----
Dihydromorphine ................................. | 0 | 5
2,5-Dimethylamphetamine ......................... | 15,650,000 | 15,650,000
Dimethylamphetamine ............................. | 2 | 7
Ethylamine analog of Phencyclidine .............. | 0 | 5
N-Ethylamphetamine .............................. | 4 | 9
Lysergic acid diethylamide ...................... | 41 | 56
Mescaline ....................................... | 2 | 7
Methaqualone .................................... | 2 | 7
Methcathinone ................................... | 9 | 14
4-Methoxyamphetamine ............................ | 12 | 17
4-Methylaminorex ................................ | 2 | 2
3,4-Methylenedioxyamphetamine ................... | 12 | 17
3,4-Methylenedioxy-N-ethylamphetamine ........... | 2 | 27
3,4-Methylenedioxymethamphetamine ............... | 12 | 17
3-Methylfentanyl ................................ | 12 | 14
Normethadone .................................... | 0 | 5
Normorphine ..................................... | 2 | 7
Tetrahydrocannabinols ........................... | 35,000 | 35,000
Thiophene Analog of Phencyclidine ............... | 10 | 10
Schedule II: | |
Alfentanil ...................................... | 7,000 | 7,000
Amobarbital ..................................... | 5 | 15
Amphetamine ..................................... | 1,026,100 | 1,026,100
Cocaine ......................................... | 550,000 | 550,000
Codeine (for sale) .............................. | 67,312,000 | 67,312,000
Codeine (for conversion) ........................ | 16,181,000 | 16,181,000
Desoxyephedrine ................................. | 900,000 | 1,154,000
(1,138,000 grams of levo-desoxyephedrine for use in a non-controlled, non-
prescription product and 16,000 grams for methamphetamine)
Dextropropoxyphene ................................ | 124,012,000 | 124,012,000
Dihydrocodeine .................................... | 202,000 | 100,000
Diphenoxylate ..................................... | 688,000 | 346,000
Ecgonine (for conversion) ......................... | 650,000 | 650,000
Ethylmorphine ..................................... | 0 | 10
Fentanyl .......................................... | 76,000 | 52,000
Hydrocodone ....................................... | 8,474,000 | 8,474,000
Hydromorphone ..................................... | 404,000 | 404,000
Isomethadone ...................................... | 0 | 10
Levo-alpha-acetylmethadol ......................... | 200,000 | 200,000
Levorphanol ....................................... | 8,000 | 8,000
Meperidine ........................................ | 8,637,000 | 9,521,000
Methadone ......................................... | 3,779,000 | 3,779,000
Methadone (for conv)............................... | 364,000 | 364,000
Methadone Intermediate (for sale) ................. | 300,000 | 0
Methadone Int. (for conv) ......................... | 4,393,000 | 4,393,000
Methylphenidate ................................... | 8,886,000 | 10,410,000
Morphine (for sale) ............................... | 7,612,000 | 7,612,000
Morphine (for conv) ............................... | 78,105,000 | 78,105,000
Noroxymorphone (for sale) ......................... | 21,000 | 21,000
Noroxymorphone (for conv) ......................... | 3,500,000 | 3,500,000
Opium ............................................. | 1,118,000 | 1,304,000
Oxycodone (for sale) .............................. | 3,613,00 | 4,254,000
Oxycodone (for conv) .............................. | 23,000 | 25,500
Oxymorphone ....................................... | 9,200 | 10,200
Pentobarbital ..................................... | 15,706,000 | 15,706,000
Phencyclidine ..................................... | 52 | 72
Phenylacetone (for conv) .......................... | 3,528,000 | 3,528,000
1-Phenylcyclohexylamine ........................... | 0 | 10
1-Piperidinocyclohexanecarbonitrile ............... | 0 | 10
Secobarbital ...................................... | 480,000 | 322,000
Sufentanil ........................................ | 1,600 | 1,600
Thebaine .......................................... | 9,383,000 | 9,383,000
----------------------------------------------------+---------------+-----------------
All interested persons are invited to submit their comments
and objections in writing regarding this proposal. A person
may object to or comment on the proposal relating to any of
the above mentioned substances without filing comments or objections
regarding the others. If a person believes that one or more
of these issues warrant a hearing, the individual should so
state and summarize the reasons for this belief.
In the event that comments or objections to this proposal
raise one or more issues which the Deputy Administrator finds
warrant a hearing, the Deputy Administrator shall order a public
hearing by notice in the Federal
---- page 24651 ----
Register, summarizing the issues to be heard and setting the
time for the hearing.
The Office of Management and budget has determined that notice
of aggregate production quotas are not subject to centralized
review under Executive Order 12866.
Rules establishing aggregate production quotas for controlled
substances in Schedules I and II are required by statute, fulfill
United States obligations under the Single Convention on Narcotic
Drugs, 1961, and other international treaties, and are essential
to a criminal law enforcement function of the United States.
Without the periodic establishment and adjustment of aggregate
production quotas, pharmaceutical manufacturers in the United
States could not lawfully produce a wide variety of medically
necessary pharmaceutical drugs.
These actions have been analyzed in accordance with the principles
and criteria contained in Executive Order 12612 and it has been
determined that this matter raises no Federalism implications
which would warrant the preparation of a Federalism Assessment.
The Deputy Administrator hereby certifies that this action
will have no significant impact upon small entities whose interests
must be considered under the Regulatory Flexibility Act, 5 U.S.C.
601, et seq. The establishment and revision of annual production
quotas for Schedules I and II controlled substances is mandated
by law and by the international obligations of the United States.
Such quotas impact predominantly upon major manufacturers of
the affected controlled substances.
Dated: May 3, 1995.
Stephen H. Greene,
Deputy Administrator.
[FR Doc. 95-11370 Filed 5-8-95; 8:45 am]
BILLING CODE 4410-09-M
------------------------------------------------------
The Contents entry for this article reads as follows:
Schedules of controlled substances; production quotas:
Schedules I and II-1995 proposed aggregate, 24649
</ARTICLE>
.